30948-01-7

Usage

Uses

Used in Pharmaceutical Industry:
Cholesteryl 10-undecenoate is used as a solubilizing agent for poorly water-soluble drugs, facilitating their incorporation into formulations and improving their bioavailability. This property is crucial for the development of effective drug delivery systems.
Used in Cosmetic Industry:
In cosmetic products, cholesteryl 10-undecenoate serves as an emollient, providing a smooth texture and enhancing the skin feel. It also acts as a stabilizer in emulsions and creams, ensuring the product's consistency and longevity.
Used in Drug Delivery Systems:
Cholesteryl 10-undecenoate is utilized in the formulation of lipid-based drug delivery systems, where it aids in the encapsulation and controlled release of therapeutic agents, thereby enhancing their efficacy and reducing side effects.
Used in Microcrystals Preparation:
It is employed in the preparation of microcrystals for drug delivery, offering a promising approach to improve the solubility, stability, and bioavailability of drugs with poor water solubility.
Used in Cancer Treatment:
Cholesteryl 10-undecenoate has potential applications in the treatment of various diseases, including cancer, due to its ability to improve the delivery and bioavailability of therapeutic agents, thus enhancing their effectiveness in combating the disease.

InChI:InChI=1/C38H64O2/c1-7-8-9-10-11-12-13-14-18-36(39)40-31-23-25-37(5)30(27-31)19-20-32-34-22-21-33(29(4)17-15-16-28(2)3)38(34,6)26-24-35(32)37/h7,19,28-29,31-35H,1,8-18,20-27H2,2-6H3/t29-,31+,32+,33-,34+,35+,37+,38-/m1/s1

Upstream product

• 112-38-9 10-undecenoic acid 
• 57-88-5 cholesterol 
• 38460-95-6 undec-10-enoyl chloride 
• 57-88-5 cholesterol 

Downstream Products

• 71437-80-4 (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl isonicotinate 

Relevant academic research and scientific papers

Liquid-crystalline elastomers containing sulfonic acid groups

A series of ionic liquid-crystalline (LC) elastomers were synthesized by using chemical cross-linking agents containing sulfonic acid groups, which were siloxane-based materials. A ionic divinyl monomer 2,2′-(1,2-ethenediyl)bis[5-[(4-undecenoyloxy)phenyl]azo]benzenesulfonic acid was used as chemical cross-linking agent. Cholest-5-en-3-ol(3β)-10-undecenoate was synthesized as a liquid-crystalline monomer. The effective cross-link density of the ionic elastomers was determined by swelling experiments in organic/buffer mixtures. Their liquid-crystalline properties were characterized by DSC, POM, and SAXS. A proposed multilayer buildup containing LC segment structure and ionic cross-linking lamellar structure separated by siloxane chains was given. The ion aggregated in domains forces the siloxane chains to fold and form an irregular lamellar structure. The ionic cluster lamellae may be tangled with the rigid mesogenic groups of LC segments to form multiple blocks. Liquid-crystal mesophase region of the polymers become narrow with increasing ionic cross-linking content.

Cyclopropanation of Terminal Alkenes through Sequential Atom-Transfer Radical Addition/1,3-Elimination

An operationally simple method to affect an atom-transfer radical addition of commercially available ICH2Bpin to terminal alkenes has been developed. The intermediate iodide can be transformed in a one-pot process into the corresponding cyclopropane upon treatment with a fluoride source. This method is highly selective for the cyclopropanation of unactivated terminal alkenes over non-terminal alkenes and electron-deficient alkenes. Due to the mildness of the procedure, a wide range of functional groups such as esters, amides, alcohols, ketones, and vinylic cyclopropanes are well tolerated.

Synthesis and characterization of novel fatty acid analogs of cholesterol: In vitro antimicrobial activity

In the present study we synthesized, characterized and checked the antimicrobial activity of fatty acid analogs of cholesterol. The synthesized compounds were characterized using IR, 1H NMR, 13C NMR and mass spectral data and tested for their antimicrobial activity by disk diffusion assay with slight modifications against Gram-positive, Gram-negative strains of bacteria as well as fungal strains. Minimum inhibitory concentration (MIC) of all the synthesized compounds was also determined. Compounds 7-14 showed inhibitory action against both the groups of bacteria and four strains of fungus. In vitro antimicrobial activity of the test compounds show that the compounds 10 and 13 are excellent antibacterial agents, where as compounds 13 and 14 are the excellent antifungal agents among the eight synthesized compounds.